These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 14664144

  • 1. [Her-2/neu, Ki-67 expression and ploidy in breast carcinoma].
    Lukashina MI, Glukhova EI, Zhukova LG, Ermilova VD, Bogatyrev VN, Baryshnikov AIu.
    Arkh Patol; 2003; 65(5):25-9. PubMed ID: 14664144
    [Abstract] [Full Text] [Related]

  • 2. Flow cytometry vs. Ki67 labelling index in breast cancer: a prospective evaluation of 181 cases.
    Martínez-Arribas F, Núñez MJ, Piqueras V, Lucas AR, Sánchez J, Tejerina A, Schneider J.
    Anticancer Res; 2002; 22(1A):295-8. PubMed ID: 12017306
    [Abstract] [Full Text] [Related]

  • 3. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
    Ottesen GL.
    APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
    [Abstract] [Full Text] [Related]

  • 4. Her2/neu analysis in formalin-fixed, paraffin-embedded breast carcinomas: comparison of immunohistochemistry and multiparameter DNA flow cytometry.
    Leers MP, Hoop JG, Nap M.
    Anticancer Res; 2003; 23(2A):999-1006. PubMed ID: 12820338
    [Abstract] [Full Text] [Related]

  • 5. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.
    Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P.
    Breast J; 2005; 11(4):278-80. PubMed ID: 15982396
    [Abstract] [Full Text] [Related]

  • 6. DNA ploidy, proliferation, and neu-oncogene protein overexpression in breast carcinoma.
    Lee AK, Wiley B, Loda M, Bosari S, Dugan JM, Hamilton W, Heatley GJ, Cook L, Silverman ML.
    Mod Pathol; 1992 Jan; 5(1):61-7. PubMed ID: 1347424
    [Abstract] [Full Text] [Related]

  • 7. Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma.
    Tawfik OW, Kimler BF, Davis M, Donahue JK, Persons DL, Fan F, Hagemeister S, Thomas P, Connor C, Jewell W, Fabian CJ.
    Histopathology; 2006 Feb; 48(3):258-67. PubMed ID: 16430472
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Correlation of HER-2/neu protein overexpression with other prognostic and predictive factors in invasive ductal breast cancer.
    Ivkovic-Kapicl T, Knezevic-Usaj S, Djilas-Ivanovic D, Panjkovic M.
    In Vivo; 2007 Feb; 21(4):673-8. PubMed ID: 17708365
    [Abstract] [Full Text] [Related]

  • 10. Her-2/neu oncogene expression in Puerto Rican females with breast cancer.
    Peredo R, Sastre G, Serrano J, Hunter Mellado R.
    Cell Mol Biol (Noisy-le-grand); 2001 Sep; 47(6):1025-32. PubMed ID: 11785652
    [Abstract] [Full Text] [Related]

  • 11. HER-2/neu oncogene expression and DNA ploidy analysis in breast cancer.
    Bacus SS, Bacus JW, Slamon DJ, Press MF.
    Arch Pathol Lab Med; 1990 Feb; 114(2):164-9. PubMed ID: 1967930
    [Abstract] [Full Text] [Related]

  • 12. COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features.
    Perrone G, Santini D, Vincenzi B, Zagami M, La Cesa A, Bianchi A, Altomare V, Primavera A, Battista C, Vetrani A, Tonini G, Rabitti C.
    Histopathology; 2005 May; 46(5):561-8. PubMed ID: 15842638
    [Abstract] [Full Text] [Related]

  • 13. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR, Abd-Elwahed SR, Abdulwahed AR.
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [Abstract] [Full Text] [Related]

  • 14. DNA flow cytometry but not telomerase activity as predictor of disease-free survival in pT1-2/N0/G2 breast cancer.
    Pinto AE, André S, Pereira T, Silva G, Soares J.
    Pathobiology; 2006 Jun; 73(2):63-70. PubMed ID: 16943686
    [Abstract] [Full Text] [Related]

  • 15. Her-2/neu expression in breast cancer--A comparison of different diagnostic methods.
    Benöhr P, Henkel V, Speer R, Vogel U, Sotlar K, Aydeniz B, Reiser A, Neubauer H, Tabiti K, Wallwiener D, Clare SE, Kurek R.
    Anticancer Res; 2005 Jun; 25(3B):1895-900. PubMed ID: 16158923
    [Abstract] [Full Text] [Related]

  • 16. Id4 messenger RNA and estrogen receptor expression: inverse correlation in human normal breast epithelium and carcinoma.
    de Candia P, Akram M, Benezra R, Brogi E.
    Hum Pathol; 2006 Aug; 37(8):1032-41. PubMed ID: 16867866
    [Abstract] [Full Text] [Related]

  • 17. Do we need HER-2/neu testing for all patients with primary breast carcinoma?
    Taucher S, Rudas M, Mader RM, Gnant M, Dubsky P, Bachleitner T, Roka S, Fitzal F, Kandioler D, Sporn E, Friedl J, Mittlböck M, Jakesz R.
    Cancer; 2003 Dec 15; 98(12):2547-53. PubMed ID: 14669272
    [Abstract] [Full Text] [Related]

  • 18. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
    Sharif MA, Mamoon N, Mushtaq S, Khadim MT.
    J Coll Physicians Surg Pak; 2009 Feb 15; 19(2):99-103. PubMed ID: 19208313
    [Abstract] [Full Text] [Related]

  • 19. HMGA1 protein overexpression in human breast carcinomas: correlation with ErbB2 expression.
    Chiappetta G, Botti G, Monaco M, Pasquinelli R, Pentimalli F, Di Bonito M, D'Aiuto G, Fedele M, Iuliano R, Palmieri EA, Pierantoni GM, Giancotti V, Fusco A.
    Clin Cancer Res; 2004 Nov 15; 10(22):7637-44. PubMed ID: 15569996
    [Abstract] [Full Text] [Related]

  • 20. Expression profiling of breast tumors based on human epidermal growth factor receptor 2 status defines migration-related genes.
    Cuadros M, Cano C, López FJ, López-Castro R, Concha A.
    Pathobiology; 2013 Nov 15; 80(1):32-40. PubMed ID: 22832278
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.